Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

JUNS Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: June 15, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Jupiter Neurosciences Inc (JUNS)

Based on 7 analysts giving stock ratings to Jupiter Neurosciences Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
29
Buy
57
Hold
14
Sell
0
Strong Sell
0
Jupiter Neurosciences Inc

Jupiter Neurosciences Inc. Stock Analysis JUNS

United States Health Care Nano Cap Report:
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 5 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Read More

Jupiter Neurosciences Inc (JUNS) Chart

Key Statistics of Jupiter Neurosciences Inc (JUNS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.24$0.24

Today's Open

$0.24

Volume

5.31M

P/E Ratio (TTM)

-

52 Week Range

$0.17$3.33

Market Cap

9.82M

Avg. Volume

3.31M

Dividend Yield

-

Financial Metrics & Statements of Jupiter Neurosciences Inc (JUNS)

FAQ's for Jupiter Neurosciences Inc (JUNS)

  • According to Musaffa’s Shariah screening methodology, Jupiter Neurosciences Inc (JUNS) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Jupiter Neurosciences Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Jupiter Neurosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Jupiter Neurosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Jupiter Neurosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Jupiter Neurosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.